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Introduction
Thymomas are rare neoplasms that arise in the anterior 
mediastinum [1]. The rate of thymoma recurrence after 
thymectomy is 10% to 29%, and patients diagnosed with 
thymoma can relapse many years after initial treatment [2-
4]. Because of the relatively small incidence of thymoma, 
as well as rates of recurrence, delayed recurrence, and 
variable patterns of recurrence, it is difficult to accurately 
validate effective management strategies. Some authors 
have suggested a surgical approach whenever possible in the 
case of recurrent thymic tumors, reporting good long-term 
survivals even after reoperation [5]. Others have supported 
and recommended chemotherapy or radiotherapy (RT) [3,6] 
(Fig. 1). No significant difference in survival rates between 
operative and non-operative management strategies have 
been found, and surgical treatment has been discouraged due 
to excessive perioperative morbidity [4,7]. To date, the lack of 
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published data has resulted in a lack of consensus on standard 
management of recurrent thymoma. 
Given the sensitivity of these tumors to radiation, RT 
has been generally adopted to eradicate potential residual 
tumor burdens following surgery [8,9], and has become the 
definitive treatment for unresectable disease [10]. However, 
the appropriate role of salvage RT in the treatment of 
recurrent tumors remains unclear. This retrospective study was 
designed to (1) assess clinical outcomes after RT in treatment 
of recurrent thymoma, (2) analyze the prognosis factors of 
recurrent thymoma, and (3) analyze the patterns of failure in 
recurrent thymoma.
Materials and Methods
1. Patients and treatment
Fifty-eight patients with histologic diagnoses of recurrent 
thymoma and thymic carcinoma who were treated with 
salvage RT at Yonsei Cancer Center from August 2007 to 
December 2015 were considered for participation in the study. 
Among these 58 patients, some underwent salvage RT for the 
first recurrence, and some underwent other treatments for 
the first few recurrences but continued to have their disease 
return. For recurrent thymoma, surgery was considered as 
standard treatment, but salvage RT was performed in patients 
who had difficult for surgery. To meet the eligibility criteria 
of salvage RT, we considered patients: (1) with inoperable 
lesions or multiple lesions, (2) with poor performance status, 
and (3) who refused surgery. Eleven were excluded: 4 who 
had no available clinical records, 3 who had incomplete RT of 
<20 Gy, and 4 patients who had undergone surgery before 
RT. As a result, 47 patients were determined eligible for the 
final analysis. Patients were staged according to the Masaoka 
staging system. Tumor histology was classified according to 
the World Health Organization histology classification system. 
Clinical data at the time of initial diagnosis including age, 
histology type, initial stage, use of surgery, use of RT, and 
pathologic findings were collected. In addition, clinical data at 
Fig. 1.  Excellent response of a recurrent tumor to salvage radiotherapy. (A) Pretreatment simulation computed tomography (CT) scan 
showing a recurrent tumor (arrow). The patient underwent salvage radiotherapy with a first plan dose of 40 Gy in 20 fractions. (B) 
Simulation CT scan during radiotherapy for adaptive planning showing the rapid shrinkage of tumor (arrow). The patient underwent 
adaptive radiotherapy with a second plan dose of 12 Gy in 5 fractions. (C) CT scan 3 months after radiotherapy showing the complete 
remission (arrow). (D) Pretreatment simulation CT scan showing a recurrent tumor (arrow). The patient underwent salvage radiotherapy 
with a first plan dose of 40 Gy in 20 fractions. (E) Simulation CT scan during radiotherapy for adaptive planning showing the rapid 
shrinkage of tumor (arrow). The patient underwent adaptive radiotherapy with a second plan dose of 14 Gy in 7 fractions. (C) Positron 
emission tomography-computed tomography (PET-CT) scan 3 months after radiotherapy showing the partial remission (arrow).
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the time of disease recurrence such as the recurrence interval, 
recurrence site, number of recurrent lesion, RT modality, RT 
dose, and use of chemotherapy, were collected. After salvage 
RT was performed, treatment outcomes were evaluated. To 
account for various fractionation schedules, all calculations 
regarding radiation dose effects were performed using the 
equivalent dose in 2-Gy fractions (EQD2) with an α/β value of 
10. The informed consent was waived. 
2. Follow-up assessment and patterns of failure
Patients were assessed using chest computed tomography 
1 month after completing RT, and afterwards, generally every 
3 to 6 months. Patterns of failure were classified according 
to relative location between the recurrence site and radiation 
isodose curve. In-field recurrence was defined as recurrence 
that occurred where the radiation dose was 100% or more. 
Marginal recurrence was defined as recurrence that occurred 
where the radiation dose was <100% and >50%. Out-of-field 
recurrence was defined as intrathoracic recurrence outside 
the 50% isodose curve. Distant recurrence was defined as 
recurrence outside the thoracic region [11]. In addition, tumor 
responses 3 months after RT were evaluated as complete 
responses, partial responses, stable disease, and progressive 
disease using the modified Response Evaluation Criteria in 
Solid Tumors. 
3. Statistical analysis
Progression-free survival (PFS) was calculated from the 
date of first progression to the date of next progression or 
death. Overall survival (OS) was calculated from the date of 
progression to the date of the patient’s death. In the absence 
of either a second progression or death, patients were assessed 
according to the date of the last follow-up visit. Both OS and 
PFS rates were calculated using the Kaplan–Meier method, 
and significance of differences in survival rates was assessed 
using a log-rank test. Multivariate Cox regression analysis was 
used to identify independent prognostic factors. A chi-square 
test was used to compare categorical variables, and a t-test 
was used to compare continuous variables. A p-value <0.05 
was considered statistically significant. SPSS version 23 (IBM, 
Armonk, NY, USA) software was used for all statistical analyses. 
Results
1. Patients and treatments
Patient and treatment characteristics at the time of initial 
diagnosis are described in Table 1. Median age was 56 years 
Table 1. Patient and tumor characteristics at initial diagnosis
Characteristic Value
Age (yr) 56 (27–87)
Sex
Male 29 (61.7)
Female 18 (38.3)
Histology
Type B2 12 (25.5)
Type B3 10 (21.3)
Type C 23 (48.9)
Unknown 2 (4.2)
Initial tumor stage
I 3 (6.4)
IIA 6 (12.8)
IIB
III 11 (23.4)
IVA 11 (23.4)
IVB 9 (19.1)
Unknown 6 (12.8)
Tumor size (cm)
<5 7 (14.9)
5–9.9 23 (48.9)
≥10 8 (17.1)
Unknown 9 (19.1)
Initial treatment
Surgery + adjuvant RT 29 (61.7)
Surgery alone 9 (19.1)
Chemotherapy 6 (12.8)
Chemoradiotherapy 2 (4.2)
RT alone 1 (2.1)
Resection margin
R0 15 (39.5)
R1 6 (15.8)
R2 8 (21.1)
Unknown 9 (24.3)
RT technique
3D CRT 30 (93.8)
IMRT 2 (6.2)
RT dose (EQD2)
<54 Gy 12 (37.5)
≥54 Gy 18 (56.3)
Unknown 2 (6.2)
Values are presented as median (range) or number (%).   AAAAA 
RT, radiotherapy; 3D CRT, three-dimensional conformal radiother-
apy; IMRT, intensity-modulated radiotherapy; EQD2, equivalent 
dose in 2-Gy fractions.
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(range, 27 to 87 years). The most frequent histologic type at 
initial diagnosis was type C, accounting for 23 cases (49%), 
12 patients (26%) had type B2, and 10 patients (21%) had 
type B3. The most common initial treatment was surgery 
with adjuvant RT, accounting for 29 cases (62%), followed by 
surgery only (19%), and chemotherapy (13%). During initial 
surgery, R0 resection was achieved in 15 patients (40%), 
while R1 and R2 resection were achieved in 6 patients (16%) 
and 8 patients (21%), respectively. Among the patients who 
underwent RT for their initial treatment, most received three-
dimensional conformal RT (94%). 
Patient and treatment characteristics at the time of disease 
recurrence are described in Table 2. The median time interval 
from initial diagnosis to recurrence was 30 months (range, 1 
to 223 months). The most common recurrent site was pleura, 
accounting for 19 cases (40%), followed by lung parenchyme 
(21%), and extrathoracic sites (19%). Twenty-nine patients 
(62%) underwent salvage RT using three-dimensional 
conformal RT, while 18 patients (38%) received salvage RT 
using intensity-modulated RT. The salvage RT field surrounded 
the gross tumor, and the planning target volume was defined 
using a 3 mm wide margin around the gross tumor volume. 
The salvage RT dose in EQD2 prescribed to treat tumors varied 
from a minimum of 30 Gy to a maximum of 70 Gy with a 
median of 52 Gy. Sixteen patients (34%) underwent additional 
chemotherapy. The retrospective protocol was approved by our 
institutional review board. The informed consent was waived.
2. Survival analysis
Median follow-up time was 83 months (range, 8 to 299 
months). Seventeen of 47 patients (36%) had died by the 
time of analysis. All 17 deaths were caused by the progression 
of thymic malignancy. The most common cause of death 
was respiratory failure as a consequence of progressive 
intrathoracic disease (n = 15). The other causes were septic 
shock (n = 1) and brain hemorrhage (n = 1). Median OS of 
all patients was 45 months, and median PFS was 23 months. 
The 5-year OS and PFS for all patients were 70% and 22%, 
respectively (Fig. 2). 
3. Response and pattern of failure
Table 3 shows response at 3 months after salvage RT in all 
47 patients. The overall response rate was 97.9%. Complete 
response was found in 18 patients (38.2%), partial response 
was found in 19 patients (40.5%), and stable disease was 
found in 9 patients (19.1%). 
Table 4 shows the patterns of failure after salvage RT in 
34 patients who had a second recurrence. Relapses were 
found at the following sites: in-field (2 patients), marginal 
(3), intrathoracic out-of-field (23), and distant (6). The most 
frequent relapse pattern after salvage RT was intrathoracic 
out-of-field, accounting for 55.8% of all failures. In contrast, 
the in-field failure rate accounted for only 5.8% of all failures, 
including the location of mediastinum (1 patient) and sacrum 
(1). Distant failure was observed in liver (2 patients), kidney (1), 
brain (1), rectum (1), and multiple sites (1). 
4. Prognostic factors
Table 2. Clinical and treatment characteristics at the time of 
disease recurrence
Characteristic Value
Recurrence interval (mo) 30 (1–223)
<30 25 (53.2) 
≥30 22 (46.8) 
Recurrent tumor histology
Type B2 7 (14.9) 
Type B3 4 (8.5) 
Type C 5 (10.6) 
Unknown 31 (66.0) 
Recurrence site
Initial tumor bed 4 (8.5) 
Pleura 19 (40.4) 
Lung parenchyme 10 (21.3) 
Extrathoracic metastasis 9 (19.1) 
Multiple 5 (10.6) 
Recurrence multiplicity
Single 7 (14.9) 
Multiple (intrathoracic) 31 (66.0)
Multiple (systemic) 9 (19.1) 
RT modality
3D CRT 29 (61.7) 
IMRT 18 (38.3) 
RT dose (EQD2)
<52 Gy 22 (46.8) 
≥52 Gy 25 (53.2) 
Chemotherapy
No 16 (34.0) 
Yes 31 (66.0)
Values are presented as median (range) or number (%).
RT, radiotherapy; 3D CRT, three-dimensional conformal radiother-
apy; IMRT, intensity-modulated radiotherapy; EQD2, equivalent 
dose in 2-Gy fractions.
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In univariate analyses, histology, initial treatment, and 
RT dose were significantly associated with OS. Histology, 
initial stage, initial treatment, recurrent site, and RT dose 
were significantly associated with PFS (all p < 0.05). After 
multivariate analysis, high dose remained independently 
associated with improved OS (hazard ratio [HR] = 0.32; 95% 
confidence interval [CI], 0.10–0.98; p = 0.046), while type C 
thymoma remained independently associated with poor OS (HR 
= 6.70; 95% CI, 2.05–21.8; p = 0.002). High dose also remained 
independently associated with improved PFS (HR = 0.35; 
95% CI, 0.16–0.75; p = 0.007), and type C thymoma remained 
independently associated with poor PFS (HR = 3.82; 95% CI, 
1.76–8.26; p = 0.001) (Table 5).
When patients were divided into high (EQD2 ≥52 Gy, n = 
25) and low (EQD2 <52 Gy, n = 22) dose groups, the median 
survival rates were 49 months (high) and 39 months (low). 
The 5-year OS rates were 80% (high dose group) and 59% 
(low dose group) (p = 0.043). The median PFS of the high dose 
group was 26 months, and 18 months for the low dose group. 
The 5-year PFS rates were 30% (high dose group) and 14% (low 
dose group) (p = 0.016; Fig. 3).
Discussion and Conclusion
Thymoma is known to recur several years after surgery in 
10%–30% of patients [2-4]. Some authors recommend 
reoperation for the treatment of recurrent thymoma, and 
have demonstrated better survival rates in the complete re-
resection group [5,12]. However, complete resection may not 
be possible in some cases, due to intimacy with vital structures 
or surgical morbidity. According to the literature, the operative 
mortality of recurrent thymoma ranges from 0% to 13.3%, 
and the operative morbidity ranges from 0% to 32.1% [13]. 
Thus, some authors recommend the use of RT or chemotherapy 
over surgery [3,6]. To date, standard treatment for recurrent 
thymoma has not been established, which is not surprising, 
given the low incidence of thymoma and its relatively indolent 
biological behavior. Currently, the highest level of knowledge 
is based on a meta-analysis of 11 retrospective studies, which 
compared patients treated surgically to those treated non-
surgically [14]. This review suggested that surgery is superior 
to non-surgical treatment. However, patients in the non-
surgical group had both heterogeneous characteristics and 
Table 3. Treatment response at 3 months after salvage 
radiotherapy
Response No. (%)
Complete response 18 (38.2)
Partial response 19 (40.5)
Stable disease 9 (19.1)
Progressive disease 1 (2.1)
Table 4. Patterns of failure after salvage radiotherapy
Patterns of failure No. (%)
In-field 2 (5.8)
Marginal 7 (20.6)
Out-of-field (intrathoracic) 19 (55.8)
Distant 6 (17.6)
Fig. 2.  Kaplan–Meier estimates of (A) overall survival and (B) progression-free survival.
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heterogenous treatment modalities, including chemotherapy 
and/or RT. Also, there may have been a selection bias towards 
patients who were difficult to conduct surgery due to 
problems such as performance status and multiplicity [15]. 
Study participants included patients who underwent 
postoperative RT (n = 29), surgery alone (n = 9), chemotherapy 
alone (n = 6), chemoradiotherapy (n = 2), and RT alone (n = 1) 
as their initial treatments. However, we do not believe these 
differences in initial treatment biased our results because 
the areas that were subjected to salvage RT were RT-naïve. 
Ultimately, the purpose of this study was to determine the 
efficacy of salvage RT for recurrent thymoma. Because none of 
the various initial treatments exhibited a significant correlation 
with outcomes, all patients—including postoperative RT, 
surgery alone, chemotherapy alone, chemoradiotherapy and 
RT alone—were included and analyzed.
In this study, we demonstrated favorable oncologic 
outcomes with salvage RT. Patients with recurrent thymoma 
had an excellent response rate (98%) with salvage RT. 
Moreover, the 5-year OS of the high RT dose group was 80%, 
which was comparable to the reported outcome of patients 
who received a complete resection after tumor recurrence 
[16]. Out in several earlier reports imply that thymoma is a 
radiosensitive tumor [17-20].
In the present study, we focused on patterns of failure in 
relation to the RT field. Because there are currently few reports 
on patterns of failure in recurrent thymoma, due to the low 
prevalence of the disease, we classified the recurrence pattern 
according to the isodose curve of the salvage RT plan. As a 
result, the in-field failure rate was only 5.8% and the marginal 
failure rate was 8.8%. Given the excellent local control rates, 
our results suggest that salvage RT may be an effective 
treatment for recurrent thymoma.
The two independent prognostic factors in our investigation 
were histology and RT dose. Tumor histology is a well-known 
prognostic factor of thymoma [21]. RT dose is independently 
associated with OS and PFS. Thus, one could consider the 
high-dose RT group the curative group and the low-dose RT 
group the palliative group. However, in patients with recurrent 
thymoma, high doses are clearly associated with effective 
treatment given that dose emerged as a significant factor 
during the multivariate analysis and appeared related to the 
number of recurrent lesions that developed. This RT dose-
response relationship supports the idea of the radiosensitive 
nature of thymoma, as shown previously [18-21], along with 
the excellent response rate of 98% and rare in-field recurrence 
in this study. In the modern RT era, RT dose escalation is 
Table 5. U
nivariate and m
ultivariate analysis for overall survival and progression-free survival
Overall survival
Progression-free survival
U
nivariate
M
ultivariate
U
nivariate
M
ultivariate
H
R (95%
 CI)
p-value
H
R (95%
 CI)
p-value
H
R (95%
 CI)
p-value
H
R (95%
 CI)
p-value
Age
0.40 (0.14–1.11)
0.079
0.67 (0.35–1.28)
0.231
Sex
1.17 (0.39–3.48)
0.771
0.94 (0.48–1.82)
0.865
H
istology (type C vs. other)
4.84 (1.65–14.1)
0.040
6.70 (2.05–21.8)
0.002
3.21 (1.60–6.45)
0.001
3.82 (1.76–8.26)
0.001
Initial stage (stage IV vs. other)
0.58 (0.21–1.58)
0.290
0.51 (0.26–0.98)
0.046
0.55 (0.25–1.20)
0.137
Initial treatm
ent (surgery vs. no surgery)
5.47 (1.69–17.7)
0.005
2.10 (0.56–7.78)
0.269
5.36 (2.21–13.0)
<0.001
1.96 (0.70–5.43)
0.196
Resection m
argin (R0 vs. other)
0.46 (0.14–1.45)
0.185
0.55 (0.26–1.14)
0.108
Recurrence interval (≤ 30 vs. >30 m
o)
2.85 (0.98–8.29)
0.054
2.82 (0.78–10.2)
0.113
1.74 (0.90–3.37)
0.098
Recurrent site (pleura vs. other)
0.39 (0.12–1.21)
0.105
0.44 (0.22–0.87)
0.019
0.53 (0.24–1.16)
0.115
N
o. of recurrent lesion (1,2 vs. ≥ 3)
0.91 (0.31–2.63)
0.864
1.19 (0.60–2.34)
0.610
RT dose (≥  52 vs. < 52 G
y)
0.34 (0.12–0.97)
0.043
0.32 (0.10–0.98)
0.046
0.45 (0.23–0.87)
0.016
0.35 (0.16–0.75)
0.007
RT m
odality after recurrence (3D CRT vs. IM
RT)
1.09 (0.39–3.01)
0.864
1.21 (0.63–2.32)
0.565
Chem
otherapy after recurrence (yes vs. no)
1.28 (0.44–3.72)
0.640
1.41 (0.69–2.88)
0.343
H
R, hazard ratio; CI, confidence interval; RT, radiotherapy; 3D CRT, three-dim
ensional conform
al radiotherapy. 
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easier to achieve through the use of advanced RT technology. 
In our institution for example, four-dimensional computed 
tomography-based planning is performed that depicts the 
tumor and normal organ movement in every respiratory phase. 
Daily image guidance is performed before every treatment 
session to ensure accurate localization. These technologies 
allow increases in the dose delivered to the tumor, while 
satisfying normal organ dose constraints, making the delivery 
of higher RT doses feasible. 
This study has several l imitations.  First ,  it  uses a 
retrospective design and has a relatively small sample size. 
Second, we did not compare patients who underwent salvage 
RT to patients who only underwent salvage surgery. Third, 
RT dose regimens were not consistent, as they were selected 
according to the recurrent site or with the physician’s 
discretion. In addition, the patients underwent a variety 
of initial treatments, and therefore, the patient pool was 
somewhat heterogeneous. Therefore, our findings should 
be interpreted with some caution. Finally, for patients with 
multiple lesions, the decision to treat all lesions, or only the 
symptomatic lesions, was at the discretion of the physician. 
Some patients exhibited a complete response after initial 
treatment, whereas other experienced a partial response. There 
were also patients who underwent radiation therapy at the 
time of the first recurrence and some patients who underwent 
radiation therapy only after the second or subsequent 
recurrence. All of these factors promoted heterogeneity in the 
study sample.
This paper also has several strengths. First, there is a very 
low prevalence of thymoma, and its recurrence is a very rare 
event. This means that many clinicians have limited experience 
with RT as a treatment for this cancer. Forty-seven patients 
is a relatively small sample, but considering the rarity of 
recurrent thymoma, it would be very difficult to design and 
conduct prospective clinical trials that could adequately 
evaluate optimal treatment options. Our retrospective cohort 
treated with salvage RT for recurrent thymoma provides useful 
information for clinicians. Second, this study was designed, 
carried out, and reported by radiation oncologists, unlike most 
previous investigations which were conducted and published 
by surgeons. This has led to a limited interpretation of RT, 
especially in terms of radiation dose and failure patterns in 
relation to the RT field. In contrast, our study analyzed the 
effect of detailed RT related-parameters such as modality, 
dose, and field. 
In conclusion, we analyzed outcomes from the use 
of salvage RT in treatment of recurrent thymoma and 
demonstrated excellent response rates. We also demonstrated 
that an RT dose of EQD2 ≥52 Gy was associated with better 
PFS and OS. Our findings suggest that high-dose RT is an 
effective salvage treatment option for recurrent thymoma. 
Application of high-dose RT should be a recommended option 
in the modern RT era, in order to improve oncologic outcomes 
in cases of recurrent thymoma.
Conflict of Interest
No potential conflict of interest relevant to this article was 
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